Shares of vaccine maker Moderna hit highs of nearly $500 earlier this year. No doubt, Moderna has been an exceptional investment over the past year, soaring 350% while the S&P 500 has risen by just 29%. Two stocks I'd buy instead of Moderna are AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK).
The Zacks Analyst Blog Highlights: Microsoft, Mastercard, Pfizer, PepsiCo and Merck
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer Inc's (NYSE: PFE) Prevnar 20 pneumococcal vaccine for routine use. The CDC's Advisory Committee has also voted to recommend vaccination either with a sequential regimen of Merck & Co Inc's (NYSE: PFE) Vaxneuvance followed by Pneumovax 23 or with a single dose 20-valent pneumococcal conjugate vaccine. These updates would apply to adults 65 years or older and adults